Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Polish law aimed at lowering petrol prices takes effect - 2When a sperm whale gives birth, the mother gets help from her friends
- 3Step by step instructions to Contrast Lab Jewels and Regular Ones
- 4Find the Advantages of Careful Eating: Developing a Sound Connection with Food
- 5Vote in favor of Your Fantasy Vehicle: Which Notable Model Catches Your Heart?
- The most effective method to Pick the Right Old Consideration Administration: Key Contemplations
- Is relief in sight? Flu season still brutal but cases are declining.
- The capacity to understand people on a profound level: Exploring Life's Intricacies
- Wedding Guest Outraged That Bride and Groom, Who Are in Their 60s and Have Both Been Married Before, Registered for Gifts
- Australia PM tries to reassure public as panic buying sees fuel demand surge 400% in some regions
- See the famous winged horse Pegasus fly in the autumn night sky
- Rediscovering Experience Through Excursions: Individual Travel Stories
- Architect Frank Gehry has died: See his most iconic buildings
- A definitive Frozen yogurt Standoff: Which Flavor Rules?
